3258 articles in this topic
New evidence-based recommendations target antenatal and preoperative care to boost recovery outcomes for cesarean patients and their newborns.
The landmark DPP trial shows lifestyle intervention delays diabetes onset by 3.5 years, metformin by 2.5 years, over two decades of follow-up.
A Cochrane review of 22 RCTs finds intermittent fasting produces little to no additional weight loss compared to regular dietary advice or no intervention.
Dihydromyricetin, found in vine tea, acts as a dual senotherapeutic—suppressing SASP in fibroblasts and eliminating senescent microglia in Alzheimer's mice.
Recombinant human thymosin beta 4 reduces infarct size and cardiac dysfunction via ErbB2 signaling in both animal models and a clinical trial.
Scientists identify Tβ4 as a neuroprotective factor that rescues neuronal loss and amyloid buildup in both human fAD organoids and 5xFAD mice.
AstraZeneca's baxdrostat wins FDA approval for hypertension, offering a novel mechanism for patients uncontrolled on existing therapies.
The FDA is seeking public input on repurposing approved drugs for new uses, targeting metabolic, neurodegenerative, and rare diseases.
Trastuzumab deruxtecan wins two new FDA approvals for early HER2+ breast cancer, showing dramatic survival gains over standard therapy.
A US phase II trial confirms darolutamide combined with ADT dramatically improves survival in metastatic hormone-sensitive prostate cancer.
Baxdrostat blocks aldosterone production directly, cutting systolic BP by ~15 mmHg in resistant hypertension patients who failed other drugs.
A large retrospective study finds older men with ED face 2x higher sedative abuse risk and 50%+ greater opioid and cocaine risk.
